![Roger Tell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roger Tell
Direttore Tecnico/Scientifico/R&S presso
ISOFOL MEDICAL AB
Profilo
Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB. Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.
Posizioni attive di Roger Tell
| Società | Posizione | Inizio |
|---|---|---|
| ISOFOL MEDICAL AB | Direttore Tecnico/Scientifico/R&S | 01/02/2019 |
| VIVESTO AB | Direttore/Membro del Consiglio | 25/05/2022 |
Precedenti posizioni note di Roger Tell
| Società | Posizione | Fine |
|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Corporate Officer/Principal | 01/02/2019 |
Formazione di Roger Tell
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
13
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivesto AB
 Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Isofol Medical AB
 Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
